Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma - Quiz - MDSpire

Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma

  • By

  • Neil J. Shah

  • Yaa Ababio

  • Anthony Eccleston

  • Dharanija Rao

  • Scott P. Kelly

  • Jane Chang

  • Sarah Lucht

  • Caleb Paydar

  • Bryce A. Van Doren

  • Emily Bland

  • William John

  • Sarah Giegerich

  • JaLyna Laney

  • Bruce Feinberg

  • Kevin K. Zarrabi

  • May 21, 2026

  • 0 min

Share

Original Source(s)

Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma

  • by Neil J. Shah, Yaa Ababio, Anthony Eccleston, Dharanija Rao, Scott P. Kelly, Jane Chang, Sarah Lucht, Caleb Paydar, Bryce A. Van Doren, Emily Bland, William John, Sarah Giegerich, JaLyna Laney, Bruce Feinberg, Kevin K. Zarrabi

  • May 21, 2026

Related Content

Management of toxicities from antibody – drug conjugates in breast cancer

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer